Read this manager's filing book
Disclosed positions
Ikarian Capital, LLC: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- SPDR SERIES TRUST
- Ticker
- XBI
- Class
- ST STR SP BIOT
- Reported value
- $47,475,000
- Reported amount
- 300,000
- Unit
- SH
- Option
- Put
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001420506-26-001820Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| SPDR SERIES TRUST | XBI | ST STR SP BIOT | $47,475,000 | 300,000 | SH | Put |
| ABIVAX SA | ABVX | SPONSORED ADS | $45,454,986 | 341,100 | SH | Call |
| ABIVAX SA | ABVX | SPONSORED ADS | $43,352,978 | 328,635 | SH | None |
| KODIAK SCIENCES INC | KOD | COM | $41,287,080 | 1,059,730 | SH | None |
| ABIVAX SA | ABVX | SPONSORED ADS | $33,315,000 | 250,000 | SH | Put |
| IONIS PHARMACEUTICALS INC | IONS | COM | $31,716,000 | 400,000 | SH | Call |
| MODERNA INC | MRNA | COM | $28,012,000 | 400,000 | SH | Put |
| ALUMIS INC | ALMS | COM | $24,497,220 | 870,548 | SH | None |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $24,386,773 | 72,842 | SH | None |
| IONIS PHARMACEUTICALS INC | IONS | COM | $23,787,000 | 300,000 | SH | Put |
| VAXCYTE INC | PCVX | COM | $22,594,085 | 388,682 | SH | None |
| ANI PHARMACEUTICALS INC | ANIP | COM | $22,523,196 | 272,085 | SH | None |
| CELLDEX THERAPEUTICS INC NEW | CLDX | COM NEW | $17,804,985 | 478,500 | SH | None |
| ARCUS BIOSCIENCES INC | RCUS | COM | $15,555,555 | 504,559 | SH | None |
| RELMADA THERAPEUTICS INC | RLMD | COM | $14,866,644 | 2,148,359 | SH | None |
| CAPRICOR THERAPEUTICS INC | CAPR | COM NEW | $14,549,497 | 604,215 | SH | None |
| COGENT BIOSCIENCES INC | COGT | COM | $14,322,251 | 370,084 | SH | None |
| NEWAMSTERDAM PHARMA COMPANY | Unresolved | PUT | $13,556,000 | 400,000 | SH | Put |
| VERA THERAPEUTICS INC | VERA | CL A | $13,302,100 | 310,000 | SH | None |
| CONTINEUM THERAPEUTICS INC | CTNM | CL A | $13,241,056 | 807,874 | SH | None |
| TENAX THERAPEUTICS INC | TENX | COM NEW | $11,459,580 | 787,600 | SH | None |
| C4 THERAPEUTICS INC | CCCC | COM STK | $11,362,110 | 2,433,000 | SH | None |
| MAZE THERAPEUTICS INC | MAZE | COM | $11,309,331 | 378,999 | SH | None |
| BIOHAVEN LTD | BHVN | COM | $11,132,933 | 748,181 | SH | None |
| CONNECT BIOPHARMA HLDGS LTD | Unresolved | SHS | $10,801,710 | 4,538,534 | SH | None |
| ALTO NEUROSCIENCE INC | ANRO | COM SHS | $10,749,651 | 407,338 | SH | None |
| PHARVARIS N V | PHVS | COM | $10,680,241 | 308,856 | SH | None |
| ALUMIS INC | ALMS | COM | $10,026,282 | 356,300 | SH | Call |
| JADE BIOSCIENCES INC | JBIO | COM NEW | $9,495,694 | 427,349 | SH | None |
| DAMORA THERAPEUTICS INC | DMRA | COM NEW | $8,731,816 | 335,710 | SH | None |
| KODIAK SCIENCES INC | KOD | COM | $8,481,592 | 217,700 | SH | Call |
| CAPRICOR THERAPEUTICS INC | CAPR | COM NEW | $8,428,000 | 350,000 | SH | Call |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | COM | $8,151,000 | 100,000 | SH | Put |
| VIRIDIAN THERAPEUTICS INC | VRDN | COM | $7,807,251 | 425,000 | SH | None |
| PELTHOS THERAPEUTICS INC | PTHS | COM SHS | $7,251,459 | 256,598 | SH | None |
| ZURA BIO LTD | ZURA | CLASS A ORD SHS | $7,189,102 | 1,218,492 | SH | None |
| TECTONIC THERAPEUTIC INC | TECX | COM | $7,075,647 | 205,837 | SH | None |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $6,695,800 | 20,000 | SH | Call |
| SPRUCE BIOSCIENCES INC | SPRB | COM NEW | $6,553,224 | 121,356 | SH | None |
| HIMS & HERS HEALTH INC | HIMS | COM CL A | $6,531,170 | 188,381 | SH | None |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $6,421,957 | 126,541 | SH | None |
| PROQR THRAPEUTICS N V | PRQR | SHS EURO | $6,372,230 | 3,425,930 | SH | None |
| BRIGHT MINDS BIOSCIENCES INC | DRUG | COM NEW | $6,244,361 | 88,951 | SH | None |
| OVID THERAPEUTICS INC | OVID | COM | $6,105,503 | 2,269,704 | SH | None |
| OCUGEN INC | OCGN | COM | $6,063,348 | 3,962,972 | SH | None |
| ALPHA COGNITION INC | ACOG | COM NEW | $6,037,790 | 836,259 | SH | None |
| KYMERA THERAPEUTICS INC | KYMR | COM | $5,779,368 | 50,400 | SH | Put |
| HARROW INC | HROW | COM | $5,766,364 | 135,775 | SH | None |
| KAZIA THERAPEUTICS LTD | KZIA | SPONSORED ADS | $5,578,510 | 396,201 | SH | None |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $5,529,952 | 165,617 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 8 positions lack a resolved ticker and 30 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.